Financial Post EN

Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

Shareholders are Recommended to Vote “FOR” the Aptose BiosciencesProposed Plan of Arrangement with Hanmi Pharmaceutical Shareholders are Reminded of Voting Deadline for Upcoming Special Meeting SAN DIEGO and TORONTO, March 23, 2026 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) is pleased to announce that Glass, Lewis & Co. […]

Mar 23, 2026 &03342323202631; 11:34 UTC financialpost.com Trending 3/5

Read original on financialpost.com ↗

↗

Positive for markets

Sentiment score: +65/100

High impact Immediate effect (hours)

WHAT THIS MEANS

Glass Lewis, a leading independent proxy advisory firm, has endorsed Aptose Biosciences' proposed Plan of Arrangement with Hanmi Pharmaceutical, recommending shareholders vote in favor. This endorsement removes a significant governance hurdle for the merger transaction and increases likelihood of shareholder approval at the upcoming special meeting.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

APS

APSStock

Expected to rise

Glass Lewis endorsement significantly increases probability of shareholder approval for Hanmi merger, removing key regulatory/governance risk

↑

APTOF

APTOFStock

Expected to rise

OTC equivalent of APS; same merger catalyst applies

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Long APS/APTOF into the special meeting vote with tight stop-loss below pre-announcement levels. Proxy endorsement is typically decisive; monitor for any competing bids or shareholder dissent. Position size should reflect execution risk on cross-border pharma M&A.

KEY SIGNALS

Third-party proxy advisor endorsement reduces deal uncertaintyShareholder vote approval probability materially increasedMerger completion timeline now more predictableRemoves potential activist opposition pathway

SECTORS INVOLVED

BiotechnologyPharmaceuticalsHealthcare

Analysis generated on Mar 23, 2026 at 11:39 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

RELATED INTELLIGENCE